title: Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?
authors.affiliation: Service d'Urologie, Institut de Recherche clinique, Université catholique de Louvain, Brussels, Belgium bertrand.tombal@uclouvain.be.
authors.forename: B
authors.initials: B
authors.lastname: Tombal
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*
chemical_list: D050071:Bone Density Conservation Agents